儿童肾病治疗中超说明书用药的现状  

Status of nephrology off-label uses in the treatment of pediatrics

作　　者：李欣然 周双[1] 陈超阳[1] 马凌悦[1] 钟旭辉[1] 周颖[1] 崔一民[1] 丁洁[1] LI Xin -ran1＇2, ZHOU Shuang, CHEN Chao - yang , MA Ling - yue, ZHONG Xu - hui , ZHOU Ying , CUI Yi -min, DING Jie(1. Department of Pharmacy, Peking University First Hospital, Beijing 100034, China; 2 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, School of Public Health, Peking University, Beijing 100191, Chin)

机构地区：[1]北京大学第一医院药剂科,北京100034 [2]北京大学医学部药事管理与临床药学系,北京100191

出　　处：《中国临床药理学杂志》2018年第7期887-890,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：本文检索了改善全球肾病预后组织(KDIGO)指南、中华医学会相关指南的更新版本,结合国外Micromedex给出的Thomson分级,对儿肾超说明书用药进行了循证评价,旨在总结儿科肾病相关超说明书用药指南,规范超说明书用药的临床应用,保障用药安全。This paper retrieved an updated version of the kidney disease improving global outcomes （KDIGO） guideline and Chinese Medical As- sociation guideline. By combining Mieromedex given Thomson grade, we draw a evidence - based evaluation of off - label drug use in pediatric kidney disease. We concluded updated pediatric nephritic disease lines. Doctors and pharmacists should cause the attention, and off- label uses of drugs normatively and rationally. guide- regardofflabel uses of drugs normatively and rationally.

关 键 词：超说明书用药 霉酚酸酯 他克莫司 左旋咪唑 利妥昔单抗 

分 类 号：R979.5[医药卫生—药品]